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A b s t r a c t
Background: Clinical outcomes of patients with non-ST-segment elevation acute coronary syndrome (NSTACS) disqualified from
an invasive strategy (InvS) remain incompletely understood.
Aim: To investigate short-term results of a conservative strategy (ConS) in a real-life population of patients with NSTACS. 
Material and methods: 526 patients with NSTACS were retrospectively analysed. Of these, 335 (63.7%) patients were initially
qualified for the ConS. In the remaining 191 (36.3%) patients an InvS was applied.
Results: The most frequent reasons for disqualification from an InvS in NSTACS patients were TIMI risk score ≤ 4 (88.0%), lack of
patient consent (3.9%) and pulmonary oedema (3.0%). In the group of InvS, cardiogenic shock on admission was found in 11 (5.8%)
patients. In patients who underwent ConS and InvS 30-day mortality rate was 6.0 and 10.5% (p = 0.061), respectively, whereas 
30-day mortality in non-shock patients assigned to InvS was 7.9% (p = 0.40 vs. ConS). During primary hospitalization, 27 (8.1%)
patients with ConS and 7 (3.7%) with InvS developed symptoms of heart failure (Killip 2-4) (p = 0.049). In the group of InvS, cardio-
genic shock on admission (OR 49.5, 95% CI 125-234.2, p < 0.0001) and in patients treated conservatively heart failure during hospi-
talization (OR 27.4, 95% CI 4.8-155.2, p = 0.003) were independent predictors of 30-day mortality (c-statistics 0.70).
Conclusions: In NSTACS patients, low risk of complications at baseline was the main reason for disqualification from InvS. The
mortality rate within 30 days did not differ significantly between the two therapeutic groups. Symptoms of heart failure during hos-
pitalization were an independent predictor of death within 30 days in NSTACS patients disqualified from InvS. 
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S t r e s z c z e n i e
Wstęp: Wyniki leczenia pacjentów z ostrym zespołem wieńcowym bez uniesienia odcinka ST (NSTACS) niezakwalifikowanych do
leczenia inwazyjnego (InvS) nie są dobrze poznane.
Cel: Ocena wczesnego wyniku klinicznego strategii zachowawczej (ConS) zastosowanej w nieselekcjonowanej grupie pacjentów
z NSTACS.
Materiał i metody: Retrospektywnie przeanalizowano 526 pacjentów z NSTACS. Spośród tej grupy 335 (63.7%) pacjentów zosta-
ło pierwotnie zakwalifikowanych do ConS, pozostałych 191 (36.3%) poddano InvS.
Wyniki: Głównymi czynnikami wykluczającymi z InvS w grupie pacjentów z NSTACS były: stopień ryzyka wg skali TIMI 
≤ 4 (88,0%), brak zgody pacjenta na interwencję (3,9%) i obrzęk płuc (3,0%). Przy przyjęciu 11 (5,8%) pacjentów poddanych InvS pre-
zentowało objawy wstrząsu kardiogennego. Śmiertelność 30-dniowa wśród pacjentów z NSTACS w grupach ConS i InvS wyniosła
odpowiednio 6,0% i 10,5% (p = 0,061), a wśród chorych bez wstrząsu kardiogennego poddanych InvS 7,9% (p = 0,40 vs ConS). Pod-
czas hospitalizacji u 27 (8,1%) pacjentów poddanych ConS i 7 (3,7%) leczonych inwazyjnie rozwinęły się objawy niewydolności serca
(klasa 2–4 wg Killipa) (p = 0,049). W grupie pacjentów poddanych InvS objawy wstrząsu kardiogennego przy przyjęciu (OR 49,5, 95% CI
125–234,2, p < 0,0001), a w grupie pacjentów poddanych ConS objawy niewydolności serca podczas hospitalizacji (OR 27,4, 95% CI
4,8–155,2, p = 0,003) w sposób niezależny determinowały 30-dniową śmiertelność (c-statystyka 0.70).
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Introduction
Acute coronary syndrome (ACS) is the most severe and
life-threatening clinical manifestation of ischaemic heart
disease. Accurate and immediate diagnosis, risk
stratification based on the individual clinical situation and
adequate therapy for individual patients without time delay
are the key points to achieve proper and satisfactory short-
and long-term clinical outcomes.
From the clinical point of view it is important to
divide the whole spectrum of ACS into two different 
categories: ST-segment elevation myocardial infarction
(STEMI) [1] and non-ST-segment acute coronary
syndrome (NSTACS) [2]. While in STEMI patients
percutaneous coronary intervention undoubtedly remains
the gold standard for coronary blood flow restoration,
the recommended treatment strategy for NSTACS
subjects still depends on early risk stratification [3-7].
Irrespective of differences in pathophysiology and
treatment of choice, 6-month mortality is about 12-13%
and remains comparable in all types of ACS [3, 4]. At
longer observation times patients with non-ST segment
elevation myocardial infarction (NSTEMI) are at two-fold
higher mortality risk than those with STEMI [5]. 
The development of new invasive therapeutic options
and medicines in combination with a deeper insight into
the underlying pathophysiology of ACS requires
modification of clinical management algorithms that enable
treatment optimization of NSTACS and achievement of
better short- [6-8] and long-term clinical outcomes [7, 9].
Algorithms and guidelines for ACS management are based
on large, controlled clinical trials that include primarily
selected patients differing from ACS patients in everyday
clinical practice. Undoubtedly, percutaneous coronary
intervention remains the most suitable and effective way
of treatment in high risk patients with NSTACS, and its
advantages over conservative strategy are widely described
[2, 6-9]. However, the real life reasons leading to
disqualification from an invasive strategy are varied and
do not necessarily reflect the estimated risk in the
approved scoring systems. 
We sought to investigate both the reasons for
disqualification from an invasive strategy and early, in-
hospital and 30-day mortality in a group of consecutive,
unselected NSTACS patients primarily qualified to receive
conservative treatment. We also compared these results
with NSTACS patients treated invasively at the same time
in our department. 
Material and methods
Study group
For the period from 1 January to 31 December 2005,
physicians from 20 hospitals in Krakow and surrounding
towns and emergency ambulance units submitted 1604 pa -
tients with ACS for coronary intervention to the duty doctor
of the John Paul II Hospital in Krakow. This group consisted
of 561 (35%) NSTACS and 1043 (65%) STEMI patients. Qualifi -
cation for invasive treatment of myocardial infarction was
performed in accordance with the current European Society
of Cardiology guidelines on STEMI [10] and NSTACS [11]
management, approved by the Polish Cardiac Society.
In cases of ACS patients without ST-segment elevation,
only high risk patients were qualified for the early invasive
strategy. For individual risk stratification TIMI Risk Score
(TRS) was used. A score of 5 points or higher was the cut-
off point for an invasive strategy. Patients with NSTACS and
signs of haemodynamic instability or recurrent myocardial
ischaemia or life-threatening arrhythmias were also
qualified for an invasive strategy, independently of TRS. 
During the first telephone contact between being
referred to the physician and to the consulting cardiologist,
the decision about subsequent therapy in each individual
case of NSTACS was made. Disqualification from early
invasive therapy was termed a conservative strategy
(ConS), and in those cases pharmacotherapy was used.
A decision for immediate interventional treatment was
termed an invasive strategy (InvS).
Based on the above criteria out of all the 561 NSTACS
cases submitted to our department, 191 (34%) patients
were qualified to receive interventional treatment, and the
remaining 370 (66%) patients were to receive conservative
therapy alone. After an assessment of all the consultation
forms for the year 2005, we asked all collaborating local
departments for permission to access the medical records
of those who were treated conservatively in those wards.
Out of 370 patients with NSTACS qualified for ConS, we
were able to assess 335 (90.5%) cases. Finally, medical
records and clinical data from collaborating departments
(335 patients) and the catheterization laboratory of our
hospital (191 patients) were collected and analysed. An
evaluation of in-hospital stay and a 30-day follow-up in
526 cases of NSTACS was conducted. The 30-day mortality
rate was estimated on the basis of data received from the
Lesser Poland Voivodal Registry of Citizens. The study
protocol was approved by the Ethical Committee of the
Jagiellonian University Medical College.
Wnioski: Najczęstszą przyczyną dyskwalifikacji pacjentów z NSTACS jako kandydatów do leczenia inwazyjnego było wyjściowo
oszacowane niskie ryzyko powikłań, a zastosowane kryteria kwalifikacji wiązały się z brakiem istotnej różnicy w 30-dniowej śmier-
telności wśród pacjentów poddanych obu strategiom terapeutycznym. Wystąpienie objawów niewydolności serca po kwalifikacji
u pacjentów poddanych strategii zachowawczej było niezależnym czynnikiem ryzyka zgonu do 30. dnia.
Słowa kluczowe: ostry zespół wieńcowy bez przetrwałego uniesienia odcinka ST, strategia zachowawcza, przezskórna inter-
wencja wieńcowa
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Clinical follow-up
The primary end-point in this study was death within
a 30-day follow-up. Secondary end-points in our
retrospective observation were: cardiogenic shock at the
time of invasive cardiology consultation, symptoms of heart
failure (Killip class 2-4) during the in-hospital period, and
delayed referral for coronary angiography or planned
invasive diagnostics of coronary arteries within 3 months
after index NSTACS. 
Statistical analysis
Statistical analyses were performed with Statistica
Version 6 (StatSoft, Inc.) software. Continuous variables
were presented as the mean value ± standard deviation
(SD) and analysed using Student’s t-test. Categorical
variables were expressed as absolute values, percentages
or both, and were compared by means of chi-square or
Fisher’s exact test. Multivariable logistic analysis was
performed to obtain independent predictors of the 30-day
mortality. The model included independent variables, such
as: symptoms of cardiogenic shock at the time of invasive
cardiology consultation, heart failure symptoms after the
invasive cardiology consultation, applied treatment strategy,
age, pharmacotherapy during the in-hospital period,
diabetes mellitus, previous myocardial infarction and
gender. The c-statistic was calculated to evaluate model
discrimination. A p value less than 0.05 was considered
statistically significant.
Results
Study groups characteristics
Patients with NSTACS in both compared groups did not
differ with regard to age, gender, arterial hypertension,
diabetes, dyslipidaemia or smoking (Tab. 1). Subjects with
NSTACS from ConS significantly less likely underwent PCI
before the analysed event (p < 0.0001) and rarely
manifested pulmonary oedema at the time of invasive
cardiology consultation (p = 0.0008), in comparison to
subjects from the InvS group. All subjects with NSTACS and
cardiogenic shock were qualified for InvS and composed
5.8% (11/191) of the group (tab. 1).
The most frequent reason for disqualification (tab. 2)
from an InvS in NSTACS patients was TIMI risk score 
≤ 4 at baseline (88.0%). Rarely was the reason for such
a decision lack of the patient’s consent for invasive
treatment (3.9%) or pulmonary oedema (3.0%). Seven (2%)
patients were excluded from InvS due to sudden cardiac
arrest with a subsequent dysfunction of the central nervous
system, present during the neurological examination.
Treatment
Patients qualified for InvS significantly more often
received a thienopyridine derivative antiplatelet drug in
comparison with the ConS group (91.4% vs. 34.5%, 
p < 0.0001) (tab. 3). Platelet GP IIb/IIIa receptor inhibitor
was used only in individuals with InvS; 15 subjects from
this group received abciximab and 5 eptifibatide. Also
heparin was more widely used in patients qualified for InvS
than ConS (95.2% vs. 86.4%, p = 0.005). 
Primary coronary angioplasty was performed in 2/3
(127/191) of subjects from the InvS group, 13.1% (25/191)
underwent coronary artery bypass graft surgery, and the
remaining 39 subjects (20.4%) were treated with
pharmacotherapy after coronary angiography. In 10.2%
(13/127) of cases from the InvS group who underwent
primary PCI, a drug-eluting stent was used during the
procedure.
InvS ConS p
Age (mean ± SD) [years] 63.7 ±10.4 65.6 ±11.3 NS
Male gender [% (n/N)] 67.5 (129/191) 59.1 (198/335) NS
Cardiovascular risk factors [% (n/N)] 
hypertension 78.0 (149/191) 80.0 (268/335) NS
diabetes 26.2 (50/191) 29.0 (97/335) NS
dyslipidaemia 34.5 (146/191) 42.1 (141/335) NS
smoking 44.5 (85/191) 43.6 (146/335) NS
Previous PCI [% (n/N)] 9.9 (19/191) 0.1 (3/335) < 0.0001
Previous CABG [% (n/N)] 6.3 (12/191) 0 –
Previous MI [% (n/N)] 28.8 (55/191) 30.1 (101/335) NS
Killip class at the time of consultation [% (n/N)]
3 10.5 (20/191) 3.3 (11/335) 0.0008
4 5.8 (11/191) 0 –
Table 1. Baseline characteristics
Tabela 1. Charakterystyka pacjentów
InvS – invasive strategy, ConS – conservative strategy, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft, 
MI – myocardial infarction
InvS – strategia inwazyjna, ConS – strategia zachowawcza, PCI – przezskórna interwencja wieńcowa, CABG – pomostowanie aortalno-wieńcowe, 
MI – zawał serca 
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Conservative strategy and clinical outcomes
Out of the patients treated with ConS in district and
regional hospitals 11 (3.3%) patients died, 85 (25.4%) were
referred directly to the local catheterization laboratory and
the remaining 239 (71.3%) were discharged home, out of
whom 20 (6.0%) had a planned hospitalization appointment
for elective coronary angiography within 3 months from the
discharge date (tab. 4). In the group of 85 subjects primarily
qualified for ConS, but transferred for delayed invasive
diagnostics to a catheterization laboratory, 7 patients died,
of whom 6 died due to the development of heart failure.
Following discharge from the hospital, but before the 30
days of follow-up, 2 additional deaths were reported. Overall
in-hospital mortality rate in the ConS group was 5.4%, and
30-day mortality 6.0% (fig. 1).
In NSTACS patients qualified to receive InvS, 9 (4.7%)
cases of in-hospital death were noted, 5 of those due to
the rapid development of cardiogenic shock; 121 (63.4%)
InvS patients after initial invasive treatment were
transferred to other wards and departments in local and
district hospitals for continuation of subsequent treatment;
and 61 (31.9%) InvS subjects were directly discharged home
in good condition when reconvalescence had been
completed (tab. 4). Out of 121 patients transferred to other
hospitals, 9 patients died. Between discharge home and
within the 30 days of follow-up, another 2 deaths were
Criterion
TIMI risk score (≤ 4) [% (n/N)] 88.0 (295/335)
1 5.1 (17/335)
2 35.5 (119/335)
3 32.2 (108/335)
4 15.2 (51/335)
No consent for invasive treatment [% (n/N)] 3.9 (13/335)
Pulmonary oedema [% (n/N)] 3.0 (10/335)
Cardiac arrest with neurological signs of CNS 2.1 (7/335)
damage [% (n/N)]
No arterial access [% (n/N)] 1.2 (4/335)
Unknown reason [% (n/N)] 1.8 (6/335)
Table 2. Criteria of qualification for conservative
strategy
Tabela 2. Kryteria kwalifikacji do strategii zacho-
wawczej
CNS – central nervous system
CNS – ośrodkowy układ nerwowy
InvS ConS p
Acetylsalicylic acid [% (n/N)] 97.9 (187/191) 98.5 (325/330) NS
Clopidogrel/ticlopidine [% (n/N)] 91.4 (172/188) 34.5 (114/330) < 0.0001
Abciximab [% (n/N)] 7.9 (15/189) 0 –
Eptifibatide [% (n/N)] 2.6 (5/189) 0 –
Unfractionated heparin [% (n/N)] 70.6 (132/187) 77.6 (256/330) NS
Low molecular weight heparin [% (n/N)] 24.6 (46/187) 8.8 (29/330) 0.0001
Table 3. Antiplatelet and anticoagulant therapy
Tabela 3. Leczenie przeciwpłytkowe i przeciwzakrzepowe
InvS – invasive strategy, ConS – conservative strategy 
InvS – strategia inwazyjna, ConS – strategia zachowawcza
InvS Hospitalization duration [day, mean ± SD] 4.5 ±3.2
N = 191 Symptoms of heart failure (Killip class 2-4), n (%) 7 (3.7)
Transfer to other ward, n (%) 121 (63.4)
Discharge home, n (%) 61 (31.9)
In-hospital mortality, n (%) 18 (9.4)
30-day mortality, n (%) 20 (10.5)
ConS Hospitalization duration [day, mean ± SD] 9.1 ±6.1
N = 335 Symptoms of heart failure (Killip class 2-4), n (%) 27 (8.1)
Transfer to catheterization laboratory, n (%) 85 (25.4)
Discharge home, n (%) 239 (71.3)
including those patients with planned coronary angiography within 3 months from discharge date 20 (6.0)
In-hospital mortality, n (%) 18 (5.4)
30-day mortality, n (%) 20 (6.0)
Table 4. 30-day clinical outcome
Tabela 4. Obserwacja 30-dniowa
InvS – invasive strategy, ConS – conservative strategy 
InvS – strategia inwazyjna, ConS – strategia zachowawcza
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reported. In-hospital mortality was estimated and reached
9.4%, whereas 30-day mortality was at the level of 10.5%
and tended to be higher (p = 0.061) than that observed in
the ConS group (fig. 1). In NSTACS patients without
cardiogenic shock treated invasively 30-day mortality
reached 7.9% (p = 0.40 vs. ConS).
The mean time of in-hospital stay completed with
home discharge in the ConS group was significantly longer
than in the case of the InvS group (mean 9.1 vs. 4.5 days,
p < 0.0001) (tab. 4). Symptoms of heart failure in Killip class
2-4 developed in 27 (8.1%) patients from the ConS and in
7 (3.7%) from the InvS group (p = 0.049).
Statistical interactions between the applied strategy
and symptoms of cardiogenic shock at the time of
consultation, and also between implemented management
and the development of heart failure after consultation
were found. In the InvS group symptoms of cardiogenic
shock on admission and in the ConS group symptoms of
heart failure during the hospitalization period were
independently correlated with the 30-day mortality rate
(c-statistic 0.70, tab. 5).
Discussion
This retrospective study demonstrates that the use of
guidelines for the management of NSTACS since 2005 has
been associated with a trend toward lower 30-day
mortality in patients treated conservatively without an
initial invasive coronary approach. However, importantly,
this group of patients was characterized by a lower risk of
cardiovascular adverse events, in comparison with those
qualified to receive invasive treatment. The aim of our
study was not only to evaluate early clinical outcomes but
also to identify potential predictors and risk factors of
unfavourable clinical outcomes in NSTACS patients. Clinical
algorithms used for risk stratification and optimization of
therapy are based on sub-analyses of large controlled trials
with clearly defined inclusion and exclusion criteria
resulting in a careful selection of patients for the study.
Therefore they do not necessarily reflect questions needed
to be answered in everyday clinical practice. 
In our NSTACS population allocation to the two
therapeutic groups was based on risk estimation with the
TRS [8]. Nearly in 90% of patients with NSTACS qualified
for an early conservative strategy the overall risk did not
exceed 4 points in the TRS. Originally the TRS system was
based on treatment outcomes observed in patients with
NSTACS from the TIMI11B clinical trial [12]. The predictive
value of the scoring system was later verified in the
TIMI11B and ESSENCE trials [12, 13]. A score of four points
in the TRS indicates that overall risk of combined endpoint
(defined as death, re-infarction and the need of urgent
revascularization) is below 12% within 14 days of follow-up.
For patients with 5 and 6-7 points in the TRS the risk was
26.2% and 40.9%, respectively. There are several possible
reasons why accuracy and predictive value of the TRS in
our population could be different from those observed in
InvS
5/191
ConS
[%
]
9/335
5/191 18/191 20/191 11/335 18/335 20/335
invasive after transfer to after discharge regional  after transfer to after discharge
cardiology non-invasive ward and before hospitals invasive and before
unit 30 days cardiology unit 30 days
all patients patients with cardiogenic shock at the time of qualification patients with heart failure after qualification (Killip class 2-4)
10
8
6
4
2
* p = 0.077, ** p = 0.061 
Fig. 1. 30-day mortality
InvS – invasive strategy, ConS – conservative strategy
Ryc. 1. Śmiertelność 30-dniowa
InvS – strategia inwazyjna, ConS – strategia zachowawcza
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the reference population of large clinical trials. First of all,
the TIMI11B trial was dedicated to a conservative treatment
strategy of NSTACS, and a planned invasive approach was
one of the exclusion criteria. Secondly, there was a different
distribution of patients with predefined levels of risk
according to estimated TRS in our and reference population.
The percentage of patients with TRS ≤ 4 in the TIMI11B
population was 83%, and in our retrospective study only
56%. This indicates that our NSTACS population was
characterized by a primarily higher risk. Despite these
differences, the risk stratification strategy based on the TRS
used in 2005 resulted in quite good 30-day survival in
unselected, consecutive patients with NSTACS qualified for
ConS. Interestingly, patients with NSTACS in the InvS group
were at much higher risk of cardiovascular adverse events
according to the TRS than those in the ConS group, and
considering the results of previous studies the mortality
rate observed in that group could be much higher [14].
Although a trend toward higher mortality was observed in
the InvS group with NSTACS, it was still comparable to that
reported in the ConS group if only subjects without
cardiogenic shock were taken into account. It is noteworthy
that the duration of primary hospitalization to discharge
was two-fold shorter in patients with InvS. Also the use of
antiplatelet agents must have had an impact on the
observed outcomes, especially in the ConS group, where
ticlopidine derivatives were used less widely. Clinical trials
completed after 2005 provided strong evidence for routine
use of these medications in ACS [1, 2]. 
Our study indicates that the main cause of poor
prognosis in NSTACS patients treated conservatively, as in 
STEMI subjects without coronary intervention [15], was the
development of acute heart failure secondary to ACS. In the
InvS group the rate of heart failure symptoms was
significantly lower. Our retrospective study also showed a low
rate of early (about 25%) and planned within 3 months after
hospital discharge (6%) invasive diagnostics in patients
primarily qualified to receive ConS. A meta-analysis of clinical
trials dedicated to ACS showed that relative mortality
reduction between subjects receiving invasive and
conservative treatment was parallel to the difference
between the percentage of patients receiving invasive
treatment in both primary InvS and ConS groups [16].
The use of the TRS for early risk stratification of
patients with NSTACS resulted in a good short-term
outcome in our study. Nevertheless, based on the
observation of STEMI patients disqualified from InvS, it can
be speculated that reconsideration of an invasive approach
as a treatment option may be beneficial at every stage of
hospitalization when acute heart failure symptoms occur.
Study limitations
Our study has several limitations, already described for
patients with STEMI [15]. First, it is a retrospective analysis
of clinical consequences of risk stratification and a decision
making algorithm used in the management of patients
with NSTACS in 2005. Second, despite our efforts, we failed
to collect data for about 35 (6.7%) patients in the
conservative treatment group. Third, due to differences in
defining ischaemia recurrence and reinfarction between
centres and the lack of an objective tool for retrospective
clarification of these states, our study did not analyse either
recurrent myocardial ischaemia or reinfarction in the
conservative strategy group. Furthermore, we did not
perform any coronary angiographic analysis in patients
Independent variable 30-day mortality
OR 95% CI p
Interaction of symptoms of cardiogenic shock at the time of consultation with  < 0.0001
applied treatment strategy
InvS (shock vs. non-shock) 49.5 12.5-234.2
Interaction of symptoms of heart failure (Killip class 2-4) after consultation with 0.003
applied treatment strategy
InvS (HF vs. non-HF) 1.14 0.35-2.43
ConS (HF vs. non-HF) 27.4 4.8-155.2
Treatment strategy (InvS vs. ConS) 1.65 0.98-3.17 0.09
Age (per year) 1.06 0.99-1.14 0.12
Clopidogrel/ticlopidine (Y/N) 0.85 0.72-1.09 0.15
Diabetes mellitus (Y/N) 0.97 0.73-1.26 0.50
Previous myocardial infarction (Y/N) 1.59 0.41-6.19 0.51
Gender (M vs. F) 0.62 0.16-2.44 0.84
GP IIb/IIIa receptor antagonist (Y/N) 0.97 0.88-1.13 0.89
Table 5. Independent predictors of death within 30 days
Tabela 5. Niezależne czynniki ryzyka wystąpienia zgonu w ciągu 30 dni
InvS – invasive strategy, ConS – conservative strategy, shock – cardiogenic shock, HF – heart failure, Y/N – yes/no, M – male, F – female
InvS – strategia inwazyjna, ConS – strategia zachowawcza, shock – wstrząs kardiogenny, HF – niewydolność serca, Y/N – tak/nie, M – mężczyzna, F – kobieta 
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from the conservative strategy group referred for delayed
coronary angiography in other catheterization laboratories,
due to the inability to collect a sufficient amount of
angiographic data, although in our opinion such an analysis
would provide additional and important information and
a new insight into the analysed problem. 
Conclusions
In NSTACS patients, low risk of complications at
baseline was the main reason for disqualification from InvS.
The mortality rate within 30 days did not differ significantly
between therapeutic groups. Symptoms of heart failure
during hospitalization were an independent predictor 
of death within 30 days in NSTACS patients treated
conservatively. 
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